News

This episode of the Invent podcast features our director of cellular phenotyping Davide Danovi discussing innovations in cell ther...

Lead candidate is encapsulated allogeneic txHepatocytes for treatment of acute liver failure, SAB expanded to include 3 global exp...

bit.bio launches first product in groundbreaking ioCRISPR-Ready Cells™ product range, paving the way for new advances in disease m...

WIRED have named 16 Trailblazer companies in Cambridge that are pushing boundaries and scaling up - including bit.bio. 

Authority Magazine interviewed bit.bio's SVP of tech ops and manufacturing Kathryn Golden to discover her path to leadership and w...

Our President and COO Kathryn Corzo talks with editor Brian Buntz from Drug Discovery & Development.

Partnership to build a platform for the development of safer and more efficient genetic engineering of human cells for cell therap...

New iPSC-derived opti-ox™ powered disease model cells with the potential to advance frontotemporal dementia research and drug disc...